We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Syros Pharmaceuticals, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 7 → 0 (-7)

100% less capital invested

Capital invested by funds: $12.4K → $0 (-$12.4K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
–
Holders Change
-7
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$9K
2
BBA
Baader Bank Aktiengesellschaft
Germany
-$1.91K
3
1CM
1492 Capital Management
Wisconsin
-$1.18K
4
XT
XTX Topco
Cayman Islands
-$290
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
1
Acadian Asset Management
Massachusetts
– -$9K -329,793 Closed
BBA
2
Baader Bank Aktiengesellschaft
Germany
– -$1.91K -83,864 Closed
1CM
3
1492 Capital Management
Wisconsin
– -$1.18K -39,244 Closed
XT
4
XTX Topco
Cayman Islands
– -$290 -10,053 Closed

SYRS Hedge Fund Activity: Q2 2025 in Review

0 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2025, worth a combined $0 — down 100% from $12.4K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SYRS and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Acadian Asset Management, exiting entirely with an estimated $9K sold.

  • 0 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2025, down from 7 in Q1 2025.
  • Funds reported $0 of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2025 and 7 closed out, a net change of -7 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2025 was Acadian Asset Management, an estimated $9K sold.

Based on aggregated 13F filings for Q2 2025.